期刊文献+

胃肠道间质瘤中p16、p27、Ki-67表达 被引量:11

Clinicopathologic study of the expression of p16, p27 and Ki-67 in gastrointestinal stromal tumors
暂未订购
导出
摘要 目的探讨胃肠道间质瘤中p16、p27和Ki67表达与临床预后的关系。方法根据核分裂象的多少、肿瘤体积的大小及有无浸润等将胃肠道间质瘤划分为良性、交界性和恶性,并运用免疫组化SP方法检测p16、p27和Ki67在胃肠道间质瘤中的表达,并统计分析其良性、交界性、恶性和复发死亡病例中的表达差异。结果p16、p27和Ki67的阳性表达率分别为48%、26%和24%。p16在良、恶性中的表达无明显差异,但在良性和交界性中的表达与复发和转移相关;p27低标记指数和Ki67高标记指数与复发和转移相关。结论p16、p27和Ki67在胃肠道间质瘤中的表达对判断预后有价值。 Purpose To investigate the correlation between clinical prognosis and expression of p16, p27 and Ki-67 in gastrointestinal stromal tumors (GISTs). Methods The cases were grouped into benign, borderline and malignance according to the size, mitosis aggression and metastases by microscopy, p16, p27 and Ki-67 were examined in every group by immunohistochemical method and the difference among those groups was statisticed and analyzed respectively. Results p16 protein, p27 labeling index(p27 LI) and Ki-67 labeling index( Ki-67 LI) were showed 48% ,26% and 24% positive in respective. The expression of p16 protein was no different among benign , borderline ,or maligant GISTs. While there was a high predictive value in the lower expression of p16 protein in groups of benign and borderline cases. Furthermore, Low p27 LI and high Ki-67 LI was related to a aggressive behavior. Conclusions The evalution of expression of p16, p27 and Ki-67 in GISTs is helpful in prognoses.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2006年第1期54-56,共3页 Chinese Journal of Clinical and Experimental Pathology
关键词 胃肠肿瘤 P16 P27 KI-67 免疫组织化学 gastrointestinal neoplasms p16 p27 Ki-67 immunohistochemistry
  • 相关文献

参考文献10

二级参考文献20

  • 1郑杰,周传农,萧枫,王秀琴.Rb、p16、细胞周期素D1蛋白在食管癌中的表达及其意义[J].中华病理学杂志,1996,25(6):336-339. 被引量:31
  • 2赵坡 杨光华 等.用非同位素PCR-SSCP法检测平滑肌肉瘤p53基因点突变[J].中华病理学杂志,1995,24:384-385.
  • 3[2]Lewin KJ, Riddell RH, Weinstein WM, et al. Gastrointestinal pathology and its clinical implications. New York:Igaku-Shoin,1992:284~341.
  • 4[3]Mazur M, Clark HB. Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol, 1983,7(6):507~19.
  • 5[4]Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumors of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology, 1994, 25(5):469~73.
  • 6[5]Miettinen M, Virolainen M, Sarlomo-Rikala M.Gastrointestinal stromal tumors: Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Pathol, 1995,19(2):207~16.
  • 7[6]Hirota S, Isozaki K, Moriiyama Y, et al. Gain-of-function mutation of C-kit in human gastrointestinal stromal tumors. Science, 1998,279(5350):577~80.
  • 8[7]Hockenbery D, Nunez G, Millimen C, et al. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 1990,348(6229):334~6.
  • 9[8]Cunningham RE, Abbondanzo SL, Chu WS, et al. Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol, 2001,9(1):19~23.
  • 10[9]Panizo-Santos A, Sola I, Vega F, et al. Predicting metastatic risk of gastrointestinal stromal tumors: Role of cell proliferation and cell cycle regulatory proteins. Int J Surg Pathol, 2000,8(2):133~44.

共引文献39

同被引文献122

引证文献11

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部